Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
And the company might one day follow Galapagos into decentralised manufacturing.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
In first-line NSCLC the drug beats chemo, and not Keytruda.
